Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAIA Biotechnology, Inc.MAIA · Entity 6919 | Director | December 30, 2022 | January 04, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAIA Biotechnology, Inc.
Report date December 30, 2022 · Filed January 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2032-12-30 | Direct | 3,045 |
Reported balance
After 2022-12-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-30 · Grant · Acquired 3,045 · Balance 3,045 F1: The stock options, granted on December 30, 2022 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options, granted on December 30, 2022 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 30, 2022 Filed Jan 4, 2023 22:47 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 3,045 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0001127602-23-000643 · form4.xml · derivative · entry 1 Vlad Laurentiu · CIK 0001913254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,045 Underlying: Common Stock · 3,045 shares Expires 2032-12-30 F1 · derivative.exercise_date: The stock options, granted on December 30, 2022 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 22:31 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 5,000 | $5.00 | $25,000.00 |
DisclosureSEC source: 0000899243-22-027451 · doc4.xml · nonDerivative · entry 1 Vlad Laurentiu · CIK 0001913254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,933 F1 · kind: These shares were purchased by the reporting person in the issuer's initial public offering, which closed on August 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.